LIR Life Sciences Corp.
0.10
EUR
-0.01
(-10.91%)
ISIN
CA50206C1005
CUSIP
50206C100
Return %
Stock
S&P 500
1Y
-43.19
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Edward Mills
- Sector
- Non-energy minerals
- Industry
- Other metals/Minerals
- Address
- Vancouver Canada
- IPO Date
- Apr 11, 2022
- Website
- lirlife.com
- Similar Companies
- Business
- LIR Life Sciences Corp. is a clinical-stage biotechnology and life sciences company focused on the development, formulation, and commercialization of next-generation drug delivery platforms for metabolic disorders, obesity, and weight management therapies. The company specializes in non-invasive delivery technologies for peptide therapeutics and glucagon-like peptide-1 (GLP-1) receptor agonists, offering alternatives to conventional subcutaneous injections. Its core product and development portfolio includes transdermal patch delivery systems for active pharmaceutical ingredients such as semaglutide, liraglutide, and tirzepatide; dissolvable microneedle array technologies designed for sustained and controlled peptide absorption; proprietary topical permeation-enhanced bio-formulations for metabolic regulation; lipolysis-targeted topical compounds; and specialized preclinical formulation, pharmacokinetic evaluation, and drug delivery optimization services for biopharmaceutical applications. LIR Life Sciences Corp. conducts its research, intellectual property development, and corporate operations primarily in Canada and the United States, targeting global healthcare markets, specialized compounding pharmacies, and biopharmaceutical licensing partners. The company was incorporated in 2021 and is headquartered in Vancouver, British Columbia, Canada. In recent developments, LIR Life Sciences Corp. completed its public listing on the Canadian Securities Exchange under the ticker symbol SKNY, establishing a dedicated capital markets presence to accelerate the commercialization of its metabolic pipeline. Over the past two years, the company executed a strategic corporate reorganization to focus exclusively on transdermal and needle-free GLP-1 therapeutic delivery systems. In addition, LIR Life Sciences Corp. entered into strategic research and formulation agreements with contract development and manufacturing organizations (CDMOs) to advance preclinical pharmacokinetic and bio-availability studies for its transdermal semaglutide patch candidates. The company has expanded its intellectual property portfolio through multiple patent applications covering novel dermal penetration enhancers and microneedle delivery matrices. Furthermore, LIR Life Sciences Corp. successfully closed equity private placement financings to fund ongoing laboratory optimization, scale-up manufacturing validation, and preparatory regulatory filings with North American health authorities.